CLINICAL TRIALS PROFILE FOR PRIVIGEN

All Clinical Trials for PRIVIGEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00750867 ↗	Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins	Completed	University of Massachusetts, Worcester	Phase 2	2008-06-01	Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only and does not alter the course of disease. Although the cause of MSA remains unclear, there is evidence of presence of common neuroinflammatory mechanisms in the MSA brains including activation of microglia and production of toxic cytokines. This research protocol is based on hypothesis that the MSA progression can be altered by blocking the neuroinflammatory activity. This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains antibodies derived from human plasma which can block the inflammatory responses in the brain that can lead to loss of brain cells.
NCT01561755 ↗	A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy	Terminated	CSL Behring	Phase 4	2012-02-01	The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
NCT01561755 ↗	A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy	Terminated	David M. Simpson	Phase 4	2012-02-01	The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
NCT02111161 ↗	Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial	Completed	CSL Behring	Phase 2	2014-04-01	The purpose of this study is to estimate the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo (saline) on the patient-reported outcome measure Physical Component Summary Score (PCS) of the SF-36 in patients with necrotizing soft tissue infections (NSTI).
NCT02111161 ↗	Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial	Completed	Anders Perner	Phase 2	2014-04-01	The purpose of this study is to estimate the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo (saline) on the patient-reported outcome measure Physical Component Summary Score (PCS) of the SF-36 in patients with necrotizing soft tissue infections (NSTI).

Clinical Trial Conditions for PRIVIGEN

Condition Name

Condition Name for PRIVIGEN
Intervention	Trials
Kidney Transplantation	2
Kawasaki Disease	1
Recurrent Pregnancy Loss	1
Scleroderma	1

Condition MeSH

Condition MeSH for PRIVIGEN
Intervention	Trials
Sclerosis	2
Lung Diseases	1
Shy-Drager Syndrome	1
Scleroderma, Diffuse	1

Clinical Trial Locations for PRIVIGEN

Trials by Country

Trials by Country for PRIVIGEN
Location	Trials
United States	5
France	2
Denmark	2
Hong Kong	1
United Kingdom	1

Trials by US State

Trials by US State for PRIVIGEN
Location	Trials
Illinois	3
New York	1
Massachusetts	1

Clinical Trial Progress for PRIVIGEN

Clinical Trial Phase

Clinical Trial Phase for PRIVIGEN
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	5
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for PRIVIGEN
Clinical Trial Phase	Trials
Recruiting	4
Completed	4
Terminated	3

Clinical Trial Sponsors for PRIVIGEN

Sponsor Name

Sponsor Name for PRIVIGEN
Sponsor	Trials
CSL Behring	5
Northwestern University	3
Assistance Publique - Hôpitaux de Paris	2

Sponsor Type

Sponsor Type for PRIVIGEN
Sponsor	Trials
Other	33
Industry	8